Feb 7, 2023 9:00 am EST Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
Jan 25, 2023 9:00 am EST Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
Jan 24, 2023 4:15 pm EST Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
Jan 13, 2023 9:00 am EST Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
Jan 5, 2023 9:00 am EST Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
Dec 28, 2022 8:00 am EST Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
Dec 22, 2022 8:00 am EST Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)